Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line.

Cioccoloni G, Aquino A, Notarnicola M, Caruso MG, Bonmassar E, Zonfrillo M, Caporali S, Faraoni I, Villivà C, Fuggetta MP, Franzese O.

J Chemother. 2020 Feb;32(1):30-40. doi: 10.1080/1120009X.2019.1694761. Epub 2019 Nov 28.

PMID:
31775585
2.

Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment Strategies.

Noguera NI, Catalano G, Banella C, Divona M, Faraoni I, Ottone T, Arcese W, Voso MT.

Cancers (Basel). 2019 Oct 18;11(10). pii: E1591. doi: 10.3390/cancers11101591. Review.

3.

Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes.

Faraoni I, Consalvo MI, Aloisio F, Fabiani E, Giansanti M, Di Cristino F, Falconi G, Tentori L, Di Veroli A, Curzi P, Maurillo L, Niscola P, Lo-Coco F, Graziani G, Voso MT.

Cancers (Basel). 2019 Sep 16;11(9). pii: E1373. doi: 10.3390/cancers11091373.

4.

Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders.

Faraoni I, Giansanti M, Voso MT, Lo-Coco F, Graziani G.

Biochem Pharmacol. 2019 Sep;167:133-148. doi: 10.1016/j.bcp.2019.04.019. Epub 2019 Apr 24. Review.

PMID:
31028744
5.

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.

Faraoni I, Graziani G.

Cancers (Basel). 2018 Dec 4;10(12). pii: E487. doi: 10.3390/cancers10120487. Review.

6.

The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-κB activation.

Faraoni I, Aloisio F, De Gabrieli A, Consalvo MI, Lavorgna S, Voso MT, Lo-Coco F, Graziani G.

Cancer Lett. 2018 Jun 1;423:127-138. doi: 10.1016/j.canlet.2018.03.008. Epub 2018 Mar 8.

PMID:
29526802
7.

Modulation of GDF11 expression and synaptic plasticity by age and training.

De Domenico E, D'Arcangelo G, Faraoni I, Palmieri M, Tancredi V, Graziani G, Grimaldi P, Tentori L.

Oncotarget. 2017 Aug 3;8(35):57991-58002. doi: 10.18632/oncotarget.19854. eCollection 2017 Aug 29.

8.

BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.

Faraoni I, Compagnone M, Lavorgna S, Angelini DF, Cencioni MT, Piras E, Panetta P, Ottone T, Dolci S, Venditti A, Graziani G, Lo-Coco F.

Biochim Biophys Acta. 2015 Mar;1852(3):462-72. doi: 10.1016/j.bbadis.2014.12.001. Epub 2014 Dec 5.

9.

Nucleophosmin/B26 regulates PTEN through interaction with HAUSP in acute myeloid leukemia.

Noguera NI, Song MS, Divona M, Catalano G, Calvo KL, García F, Ottone T, Florenzano F, Faraoni I, Battistini L, Colombo E, Amadori S, Pandolfi PP, Lo-Coco F.

Leukemia. 2013 Apr;27(5):1037-43. doi: 10.1038/leu.2012.314. Epub 2012 Nov 7.

PMID:
23183427
10.

MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status.

Faraoni I, Laterza S, Ardiri D, Ciardi C, Fazi F, Lo-Coco F.

J Hematol Oncol. 2012 Jun 8;5:26. doi: 10.1186/1756-8722-5-26.

11.

miR-155 gene: a typical multifunctional microRNA.

Faraoni I, Antonetti FR, Cardone J, Bonmassar E.

Biochim Biophys Acta. 2009 Jun;1792(6):497-505. doi: 10.1016/j.bbadis.2009.02.013. Epub 2009 Mar 5. Review.

12.

Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro.

Rossi L, Bonmassar E, Faraoni I.

Pharmacol Res. 2007 Sep;56(3):248-53. Epub 2007 Jul 10.

PMID:
17702597
13.

A novel telomerase-based approach to detect natural cell-mediated cytotoxic activity against tumor cells in vitro.

Faraoni I, Cottarelli A, Giuliani A, Bonmassar L, Rossi L, Bonmassar E.

J Immunol Methods. 2005 Oct 30;305(2):162-72. Epub 2005 Aug 16.

PMID:
16165149
14.

Preclinical studies on detection of circulating melanoma cells in patients: telomerase as a recognition marker of malignancy.

Bonmassar L, Massara MC, Cottarelli A, Aquino A, Formica V, Prete SP, Lacal PM, Marchetti P, Concolino F, Faraoni I, D'Atri S.

J Chemother. 2004 Oct;16(5):479-86.

PMID:
15565916
15.

Nerve growth factor induces the re-expression of functional androgen receptors and p75(NGFR) in the androgen-insensitive prostate cancer cell line DU145.

Sigala S, Tognazzi N, Rizzetti MC, Faraoni I, Missale C, Bonmassar E, Spano P.

Eur J Endocrinol. 2002 Sep;147(3):407-15.

PMID:
12213679
16.

Stem cell factor activates telomerase in mouse mitotic spermatogonia and in primordial germ cells.

Dolci S, Levati L, Pellegrini M, Faraoni I, Graziani G, Di Carlo A, Geremia R.

J Cell Sci. 2002 Apr 15;115(Pt 8):1643-9.

17.

Clinical applications of telomerase in cancer treatment.

Faraoni I, Bonmassar E, Graziani G.

Drug Resist Updat. 2000 Jun;3(3):161-170.

PMID:
11498381
18.

Telomerase as a potential anticancer target: growth inhibition and genomic instability.

Faraoni I, Graziani G.

Drug Resist Updat. 2000 Feb;3(1):3-6.

PMID:
11498359
19.

Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells.

D'Atri S, Graziani G, Lacal PM, Nisticò V, Gilberti S, Faraoni I, Watson AJ, Bonmassar E, Margison GP.

J Pharmacol Exp Ther. 2000 Aug;294(2):664-71.

PMID:
10900246
20.

Suppression of telomerase activity as an indicator of drug-induced cytotoxicity against cancer cells: in vitro studies with fresh human tumor samples.

Faraoni I, Graziani G, Turriziani M, Masci G, Mezzetti M, Testori A, Veronesi U, Bonmassar E.

Lab Invest. 1999 Aug;79(8):993-1005.

PMID:
10462037
21.

Suppression of telomerase, reexpression of KAI1, and abrogation of tumorigenicity by nerve growth factor in prostate cancer cell lines.

Sigala S, Faraoni I, Botticini D, Paez-Pereda M, Missale C, Bonmassar E, Spano P.

Clin Cancer Res. 1999 May;5(5):1211-8.

22.

Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase.

Tentori L, Lacal PM, Benincasa E, Franco D, Faraoni I, Bonmassar E, Graziani G.

J Pharmacol Exp Ther. 1998 May;285(2):884-93.

PMID:
9580640
23.

Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide.

Tentori L, Orlando L, Lacal PM, Benincasa E, Faraoni I, Bonmassar E, D'Atri S, Graziani G.

Mol Pharmacol. 1997 Aug;52(2):249-58.

PMID:
9271347
24.

AZT inhibits the transmission of human T cell leukaemia/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro.

Macchi B, Faraoni I, Zhang J, Grelli S, Favalli C, Mastino A, Bonmassar E.

J Gen Virol. 1997 May;78 ( Pt 5):1007-16.

PMID:
9152417
25.

Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro.

Faraoni I, Turriziani M, Masci G, De Vecchis L, Shay JW, Bonmassar E, Graziani G.

Clin Cancer Res. 1997 Apr;3(4):579-85.

26.

Development of a novel in vitro chemosensitivity assay: telomerase as a possible marker of tumor cell survival.

Faraoni I, Turriziani M, Bonmasssar E, De Vecchis L, Graziani G.

J Chemother. 1996 Oct;8(5):394-8.

PMID:
8957721
27.

The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation.

De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T.

Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7149-53.

28.

O6-alkylguanine-DNA alkyltransferase attenuates triazene-induced cytotoxicity and tumor cell immunogenicity in murine L1210 leukemia.

Graziani G, Faraoni I, Grohmann U, Bianchi R, Binaglia L, Margison GP, Watson AJ, Orlando L, Bonmassar E, D'Atri S.

Cancer Res. 1995 Dec 15;55(24):6231-6.

29.

In vitro infection of leukemic bone marrow with HTLV-I generates immortalized cell lines expressing T or myeloid cell phenotype.

Giuliani A, Vernole P, D'Atri S, Del Poeta G, D'Onofrio C, Faraoni I, Greiner JW, Bonmassar E, Graziani G.

Leukemia. 1995 Dec;9(12):2071-81.

PMID:
8609719
30.

HSP70 production and inhibition of cell proliferation in Molt-4 T-cells after cell-to-cell transmission of HTLV-I: effect of PGA1.

D'Onofrio C, Puglianiello A, Amici C, Faraoni I, Lanzilli G, Bonmassar E.

Leuk Res. 1995 May;19(5):345-56.

PMID:
7769835
31.

Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene.

De Smet C, Courtois SJ, Faraoni I, Lurquin C, Szikora JP, De Backer O, Boon T.

Immunogenetics. 1995;42(4):282-90.

PMID:
7672823
32.

Transient HTLV-I infection of a human glioma cell line following cell-free exposure.

Graziani G, Faraoni I, Zhang J, Caronti B, Lauro G, Bonmassar E, Macchi B.

Virology. 1993 Dec;197(2):767-9.

PMID:
8249298
33.

Protective effect of interferon beta on human T cell leukaemia virus type I infection of CD4+ T cells isolated from human cord blood.

Macchi B, Faraoni I, Mastino A, D'Onofrio C, Romeo G, Bonmassar E.

Cancer Immunol Immunother. 1993 Jul;37(2):97-104.

PMID:
8100486
34.

Comparative anti-viral and anti-proliferative activity of PGA1 and PGJ2 against HTLV-I-infected MT-2 cells.

D'Onofrio C, Amici C, Puglianiello A, Faraoni I, Lanzilli G, Santoro MG, Bonmassar E.

Int J Cancer. 1992 May 28;51(3):481-8.

PMID:
1592539

Supplemental Content

Loading ...
Support Center